{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.52","upperLimit":"5.12","value":"1.92"},{"groupId":"OG001","lowerLimit":"0.26","upperLimit":"4.27","value":"1.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"0 to < 3 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.20","upperLimit":"6.93","value":"3.22"},{"groupId":"OG001","lowerLimit":"0.87","upperLimit":"6.21","value":"2.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"142"}],"units":"Participants"}],"title":"3 to < 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.42","upperLimit":"9.49","value":"5.18"},{"groupId":"OG001","lowerLimit":"2.98","upperLimit":"10.73","value":"6.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"title":"6 to < 12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.25","upperLimit":"12.77","value":"7.82"},{"groupId":"OG001","lowerLimit":"2.98","upperLimit":"10.73","value":"6.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"title":"12 to < 18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.74","upperLimit":"13.57","value":"8.48"},{"groupId":"OG001","lowerLimit":"2.98","upperLimit":"10.73","value":"6.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"title":"18 to < 24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.74","upperLimit":"13.57","value":"8.48"},{"groupId":"OG001","lowerLimit":"3.46","upperLimit":"11.62","value":"6.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"24 to <30 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.74","upperLimit":"13.57","value":"8.48"},{"groupId":"OG001","lowerLimit":"3.96","upperLimit":"12.52","value":"7.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"title":"30 to <36 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"description":"Defined as the cumulative incidence rate from competing risk analysis of MR from the date of randomization to hematologic malignancy relapse/recurrence.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"FAS. Cumulative incidence was calculated for participants with underlying hematologic malignant disease. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Months 3, 6, 12, 18, 24, 30, and 36","title":"Cumulative Incidence of Malignancy Relapse/Recurrence (MR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}